Anavex Life Sciences Corp (AVXL)

[TempePhil]

Steady, it appears to me that in the efficacy trials (with placebo arm), a2-73 is given in low to medium doses, so there are no problems with dosing being to high, messing up the dosing regimen.

Then the EXTENSION trials are where the dosing is really varied to obtain a plot of efficacy versus dosage. Seems like a safe way to handle dosing, though it takes a little longer because of the extension.